$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022029082 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$52.69M	$38.55M
YoY Change	10.72%	11.72%
Cost Of Revenue	$14.45M	$13.32M
YoY Change	6.53%	7.33%
Gross Profit	$38.25M	$25.23M
YoY Change	12.39%	14.19%
Gross Profit Margin	72.59%	65.45%
Selling, General & Admin	$26.92M	$26.98M
YoY Change	3.67%	18.44%
% of Gross Profit	70.38%	106.9%
Research & Development	$5.245M	$5.046M
YoY Change	33.66%	17.79%
% of Gross Profit	13.71%	20.0%
Depreciation & Amortization	$1.039M	$1.000M
YoY Change	33.21%	42.86%
% of Gross Profit	2.72%	3.96%
Operating Expenses	$32.16M	$32.02M
YoY Change	7.6%	18.34%
Operating Profit	$6.085M	-$6.788M
YoY Change	46.95%	36.83%
Interest Expense	$540.0K	$105.0K
YoY Change	800.0%	10400.0%
% of Operating Profit	8.87%
Other Income/Expense, Net	-$3.000K	$232.0K
YoY Change	-142.86%	673.33%
Pretax Income	$6.622M	-$6.556M
YoY Change	57.37%	32.95%
Income Tax	$700.0K	$21.00K
% Of Pretax Income	10.57%
Net Earnings	$5.922M	-$6.577M
YoY Change	30.61%	33.38%
Net Earnings / Revenue	11.24%	-17.06%
Basic Earnings Per Share		-$0.14
Diluted Earnings Per Share	$0.13	-$0.14
COMMON SHARES
Basic Shares Outstanding	47.22M shares	47.18M shares
Diluted Shares Outstanding		47.18M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.5M	$110.9M
YoY Change	15.61%	12.87%
Cash & Equivalents	$51.07M	$65.22M
Short-Term Investments	$68.47M	$45.72M
Other Short-Term Assets	$4.803M	$4.410M
YoY Change	13.12%	-5.89%
Inventory	$15.99M	$16.73M
Prepaid Expenses
Receivables	$46.54M	$34.30M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$186.9M	$166.4M
YoY Change	17.92%	14.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.37M	$58.55M
YoY Change	-2.81%	0.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$19.96M	$21.74M
YoY Change	-22.29%	7.43%
Other Assets	$1.303M	$1.357M
YoY Change	311.04%	519.63%
Total Long-Term Assets	$86.14M	$81.64M
YoY Change	1.05%	3.09%
TOTAL ASSETS
Total Short-Term Assets	$186.9M	$166.4M
Total Long-Term Assets	$86.14M	$81.64M
Total Assets	$273.0M	$248.0M
YoY Change	12.02%	10.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.93M	$8.113M
YoY Change	87.78%	45.52%
Accrued Expenses	$16.19M	$13.95M
YoY Change	15.27%	27.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$41.00K	$41.00K
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$37.46M	$27.00M
YoY Change	43.8%	43.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.46M	$27.00M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$80.73M	$70.18M
YoY Change	10.22%	4.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$400.0M	-$405.9M
YoY Change	4.36%	4.67%
Common Stock	$593.2M	$584.9M
YoY Change	7.1%	7.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$192.3M	$177.8M
YoY Change
Total Liabilities & Shareholders Equity	$273.0M	$248.0M
YoY Change	12.02%	10.65%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	$5.922M	-$6.577M
YoY Change	30.61%	33.38%
Depreciation, Depletion And Amortization	$1.039M	$1.000M
YoY Change	33.21%	42.86%
Cash From Operating Activities	$6.975M	$4.101M
YoY Change	-33.89%	12.85%
INVESTING ACTIVITIES
Capital Expenditures	$1.125M	-$1.409M
YoY Change	-213.52%	-42.79%
Acquisitions
YoY Change
Other Investing Activities	-$20.60M	$598.0K
YoY Change	-816.41%	-460.24%
Cash From Investing Activities	-$21.73M	-$811.0K
YoY Change	-1252.73%	-69.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	605.0K	-312.0K
YoY Change	-54.88%	-117.46%
NET CHANGE
Cash From Operating Activities	6.975M	4.101M
Cash From Investing Activities	-21.73M	-811.0K
Cash From Financing Activities	605.0K	-312.0K
Net Change In Cash	-14.15M	2.978M
YoY Change	-202.7%	6.66%
FREE CASH FLOW
Cash From Operating Activities	$6.975M	$4.101M
Capital Expenditures	$1.125M	-$1.409M
Free Cash Flow	$5.850M	$5.510M
YoY Change	-49.32%	-9.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
	dei	City Area Code CityAreaCode	617
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Local Phone Number LocalPhoneNumber	588-5555
	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q3	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35280
	dei	Entity Registrant Name EntityRegistrantName	VERICEL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MI
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3096597
	dei	Entity Address Address Line1 EntityAddressAddressLine1	64 Sidney Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Security12b Title Security12bTitle	Common Stock (No par value)
	dei	Trading Symbol TradingSymbol	VCEL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47222987	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65216000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68330000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	45724000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	35068000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	21739000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	115000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34296000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37437000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	16729000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	13381000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4410000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4246000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	166375000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	158462000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15918000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13308000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	211000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42628000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45720000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26052000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	7000000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	25687000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1357000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	317000	usd
CY2022Q3	us-gaap	Assets Assets	248017000	usd
CY2021Q4	us-gaap	Assets Assets	243705000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8113000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9016000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13948000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14045000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4902000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2950000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	27004000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43176000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47147000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	44000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	70180000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	73243000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47201000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47201000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46880000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46880000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	584900000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	553902000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1146000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-154000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405917000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383286000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	177837000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	170462000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	248017000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	243705000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38326000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33718000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	111004000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106025000	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	225000	usd
CY2021Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	788000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	667000	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	2568000	usd
CY2022Q3	us-gaap	Revenues Revenues	38551000	usd
CY2021Q3	us-gaap	Revenues Revenues	34506000	usd
	us-gaap	Revenues Revenues	111671000	usd
	us-gaap	Revenues Revenues	108593000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13318000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12408000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40132000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	36600000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	25233000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	22098000	usd
	us-gaap	Gross Profit GrossProfit	71539000	usd
	us-gaap	Gross Profit GrossProfit	71993000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5046000	usd
	vcel	Revenue Revenue Recognized Changein Uncollectible Analysis Percentage RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage	0.0050
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4284000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14698000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12363000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26975000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22775000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79984000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71625000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	32021000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	27059000	usd
	us-gaap	Operating Expenses OperatingExpenses	94682000	usd
	us-gaap	Operating Expenses OperatingExpenses	83988000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6788000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4961000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23143000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11995000	usd
	vcel	Revenue Revenue Recognized Effect Of0.5 Change In The Estimated Uncollectible Percentage Amount RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount	300000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	342000	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	44000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	578000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	163000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22600000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	105000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	1000	usd
	us-gaap	Interest Expense InterestExpense	143000	usd
	us-gaap	Interest Expense InterestExpense	3000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	98000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	44000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	232000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	30000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	533000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	204000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6556000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4931000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22610000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11791000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	215000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6577000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4931000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22631000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12006000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022Q3	vcel	Number Of Contracted Specialty Pharmacies NumberOfContractedSpecialtyPharmacies	2	pharmacy
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47182000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46669000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47096000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46355000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47182000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46669000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47096000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46355000	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6577000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4931000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	6300000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22631000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12006000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-291000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-992000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-37000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6868000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4931000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23623000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12043000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	170462000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7091000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9531000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1155000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	310000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1423000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-459000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	172485000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8963000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10808000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	428000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	318000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	18000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-242000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	174816000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6577000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9104000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	498000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	331000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	44000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-291000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	177837000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	134260000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3289000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7019000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3532000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	249000	usd
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1501000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-61000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	140209000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3786000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10866000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3531000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	309000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	61000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	24000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	151092000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4931000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8596000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1676000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	404000	usd
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	57000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	156780000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22631000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12006000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2942000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2185000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	29443000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	26481000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-305000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-737000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	36000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3120000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3420000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-21000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-17000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3348000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3703000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-3141000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-5594000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	164000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	793000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-37000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-672000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-97000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-361000	usd
	vcel	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2019000	usd
	vcel	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2410000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10712000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18489000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	43950000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	49375000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	35944000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	50913000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6471000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6924000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14477000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5386000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3040000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9701000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1076000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1485000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1619000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-39000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-252000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	440000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7830000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3325000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20933000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68541000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33831000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65216000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65200000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54764000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	137000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	45000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	482000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	85000	usd
	vcel	Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable	0	usd
	vcel	Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable	57000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65216000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54553000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	211000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65216000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54764000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets two cell therapy products in the U.S., MACI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(autologous cultured chondrocytes on porcine collagen membrane) and Epicel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(cultured epidermal autografts).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a registration-stage biological orphan product designed for the debridement of severe thermal burns. The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="padding-right:72pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-19”) to be a pandemic. This pandemic has contributed to an economic downturn on a global scale, as well as significant volatility in the financial markets. Since the pandemic’s inception, there has been significant volatility in our results of operations on a quarterly basis due to the widespread and periodic cancellation or delay of elective MACI surgical procedures throughout the U.S., staffing shortages and our ability to access customers.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the outset of the pandemic, the Company put in place a comprehensive workplace protection plan, which instituted protective measures in response to the spread of the COVID-19 virus. Vericel’s workplace protection plan has closely followed guidance issued by the Centers for Disease Control and Prevention (“CDC”) and has complied with applicable federal and state law. To date, Vericel has been successful in sustaining its operations and providing MACI and Epicel to patients in need. The Company continues to review its policies and procedures regularly, including its workplace protection plan, as the pandemic evolves and the Company may take additional actions to the extent required. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to manufacture MACI and Epicel and is maintaining a significant safety stock of all key raw materials. Vericel does not expect that current global supply chain interruptions will impact its ongoing manufacturing operations. Additionally, although the Company has not experienced material shipping delays, significant disruption of air travel could result in the inability to deliver MACI or Epicel final products to customer sites within appropriate timeframes, which could adversely impact the Company’s business. Currently, the Company is not aware of COVID-19 related impacts on its distributors, operations or third-party service providers’ ability to manage patient cases. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that a resurgence of COVID-19 because of emerging variants or other factors could result in additional disruptions that could impact our business and operations in the future, including intermittent restrictions on the ability of the Company’s personnel to travel and access customers for selling, marketing, training and case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact the Company’s capacity to manufacture, sell and support the use of our products.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The War in Ukraine</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022, the Company had an accumulated deficit of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$405.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and had a </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net loss of $22.6 million during the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September 30, 2022. The Company had cash and cash equivalents of $65.2 million and investments of $67.5 million as of September 30, 2022. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. The effects of the COVID-19 pandemic continue to evolve, however. To the extent the U.S. experiences a worsening in COVID-19 infections or additional virus variants emerge that result in more serious disease or limit the effectiveness of existing vaccines, subsequent healthcare measures – to include the postponement or cessation of elective and other surgical procedures – may cause the Company to experience a reduction in business and resulting revenue. This, consequently, may result in irrecoverable losses of customers and significantly impact the Company’s long-term liquidity, potentially requiring the Company to engage in layoffs, furloughs and/or reductions in salaries. The Company also may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all, particularly in light of the impact of COVID-19 on the global economy and financial markets. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.</span></div>
CY2022Q3	vcel	Number Of Products NumberOfProducts	2	product
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405900000	usd
CY2022Q3	us-gaap	Investments Investments	67500000	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying c</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ondensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to continue to contain or treat COVID-19, as well as the economic impact on its customers. The Company has made estimates of the impact of the COVID-19 pandemic within these financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. As of September 30, 2022, the Company has not recorded impairments to investments, inventory, other current assets or long-lived assets as a result of the COVID-19 pandemic.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These c</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ondensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on February 24, 2022 (“Annual Report”).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new accounting standards were adopted during the nine months ended September 30, 2022. The Company considers the applicability and impact of any recent Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASU’s were determined to be either not applicable or are expected to have minimal impact on the Company's condensed consolidated financial statements.</span></div>
CY2022Q3	us-gaap	Revenues Revenues	38551000	usd
CY2021Q3	us-gaap	Revenues Revenues	34506000	usd
	us-gaap	Revenues Revenues	111671000	usd
	us-gaap	Revenues Revenues	108593000	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	15797000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12676000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	883000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	644000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	49000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	61000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	16729000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	13381000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	46000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	74000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	33182000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	27630000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	17264000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	14322000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15918000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13308000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2900000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	700000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2200000	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5472000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	6305000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2897000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3616000	usd
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
CY2022Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	5417000	usd
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3973000	usd
CY2022Q3	vcel	Accrued Expenses Other Current AccruedExpensesOtherCurrent	162000	usd
CY2021Q4	vcel	Accrued Expenses Other Current AccruedExpensesOtherCurrent	151000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13948000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14045000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1700000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	5200000	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1800000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	5500000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
CY2021Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42628000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45720000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	46000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	73000	usd
CY2022Q3	vcel	Right Of Use Asset RightOfUseAsset	42674000	usd
CY2021Q4	vcel	Right Of Use Asset RightOfUseAsset	45793000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4902000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2950000	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43176000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47147000	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	44000	usd
CY2022Q3	vcel	Lease Liability Noncurrent LeaseLiabilityNoncurrent	48119000	usd
CY2021Q4	vcel	Lease Liability Noncurrent LeaseLiabilityNoncurrent	50182000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	68608000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1146000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67463000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67463000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	60909000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	154000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	60755000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	60755000	usd
	vcel	Debt Securities Available For Sale Contractual Maturity Period DebtSecuritiesAvailableForSaleContractualMaturityPeriod	P3Y
CY2021	vcel	Debt Securities Available For Sale Contractual Maturity Period DebtSecuritiesAvailableForSaleContractualMaturityPeriod	P3Y
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6577000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4931000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22631000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12006000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47182000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46669000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47096000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46355000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47182000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46669000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47096000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46355000	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-22-029082-index-headers.html	Edgar Link	pending
0001628280-22-029082-index.html	Edgar Link	pending
0001628280-22-029082.txt	Edgar Link	pending
0001628280-22-029082-xbrl.zip	Edgar Link	pending
a1012-revolvingcreditagree.htm	Edgar Link	pending
ex311ceocertificationq32022.htm	Edgar Link	pending
ex312cfocertificationq32022.htm	Edgar Link	pending
ex321ceoandcfosoxcertifica.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vcel-20220930.htm	Edgar Link	pending
vcel-20220930.xsd	Edgar Link	pending
vcel-20220930_cal.xml	Edgar Link	unprocessable
vcel-20220930_pre.xml	Edgar Link	unprocessable
vcel-20220930_lab.xml	Edgar Link	unprocessable
vcel-20220930_def.xml	Edgar Link	unprocessable
vcel-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2022 Q4 Form 10-Q Financial Statement

#000162828022029082 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2022 Q4 Form 10-Q Financial Statement

#000162828022029082 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel